The CPNE4 antibody targets Copine-4 (CPNE4), a calcium-dependent phospholipid-binding protein belonging to the copine family, which is evolutionarily conserved and involved in membrane trafficking, signal transduction, and cellular adhesion. CPNE4 is encoded by the CPNE4 gene located on human chromosome 3q21.3 and is expressed in various tissues, including the brain, lung, and testis. It plays roles in regulating intracellular pathways, such as NF-κB signaling, and has been implicated in neuronal development, synaptic plasticity, and cancer progression. Studies suggest CPNE4 may act as a tumor suppressor or promoter depending on context, with altered expression observed in gliomas, prostate cancer, and other malignancies.
In neuroscience, CPNE4 is associated with neurodegenerative diseases, potentially influencing Aβ aggregation in Alzheimer’s disease. Its calcium-dependent membrane-binding ability allows it to bridge cytoplasmic proteins with membrane phospholipids, modulating vesicle transport and receptor signaling. CPNE4 antibodies are essential tools for detecting protein expression, localization, and interaction partners via techniques like Western blot, immunohistochemistry, or immunofluorescence. Researchers utilize these antibodies to explore CPNE4's functional mechanisms in health and disease, though variability in antibody specificity across commercial sources requires careful validation for experimental reliability. Ongoing research aims to clarify its dual roles in cancer and neurodegeneration.